ストックスクリーナーアプリを入手
1.135
2.99%
-0.035
プレマーケット:
1.15
0.015
+1.32%
前日終値:
$1.17
開ける：
$1.17
24時間の取引高:
4.51M
Relative Volume:
1.33
時価総額：
$204.40M
収益：
$850.00K
当期純損益:
$-68.17M
株価収益率:
-2.7575
EPS:
-0.4116
ネットキャッシュフロー:
$-53.29M
1週間 パフォーマンス:
-38.65%
1か月 パフォーマンス:
-52.71%
6か月 パフォーマンス:
-78.71%
1年 パフォーマンス:
-67.48%
1日の値動き範囲:
$1.10
$1.17
1週間の範囲:
$1.10
$1.90
52週間の値動き範囲:
$1.10
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Compare CMPX vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.135 | 204.40M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-13 | 開始されました | Craig Hallum | Buy |
| 2026-01-05 | 開始されました | William Blair | Outperform |
| 2025-12-03 | 開始されました | Canaccord Genuity | Buy |
| 2025-12-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-07-01 | 再開されました | Raymond James | Outperform |
| 2025-04-02 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 開始されました | Guggenheim | Buy |
| 2025-02-19 | 開始されました | Piper Sandler | Overweight |
| 2024-12-23 | 開始されました | D. Boral Capital | Buy |
| 2024-11-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 開始されました | Jefferies | Buy |
| 2023-01-27 | 開始されました | Stifel | Buy |
| 2022-05-23 | 再開されました | H.C. Wainwright | Buy |
| 2022-03-15 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-01-19 | 開始されました | B. Riley Securities | Buy |
| 2021-12-22 | 開始されました | Raymond James | Outperform |
| 2021-12-20 | 開始されました | SVB Leerink | Outperform |
| 2021-12-15 | 開始されました | Wedbush | Outperform |
すべてを表示
Compass Therapeutics Inc (CMPX) 最新ニュース
How Does FDA Feedback Change the Tovecimig Path for Compass Therapeutics (NASDAQ:CMPX)? - Kalkine Media
Compass Therapeutics Is Maintained at Market Outperform by Citizens - Moomoo
Compass Therapeutics Shares Drop After Downgrade From Wedbush - marketscreener.com
Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX) - Seeking Alpha
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’ - Stocktwits
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Citizens maintains Market Outperform rating on Compass Therapeutics, $4 price target - TradingView
Guggenheim maintains Buy rating on Compass Therapeutics, $4 price target - TradingView
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 - marketscreener.com
Wedbush downgrades Compass Therapeutics to Neutral, sets price target to $1 - TradingView
Cantor Fitzgerald reiterates Compass Therapeutics stock rating By Investing.com - Investing.com Canada
H.C. Wainwright cuts Compass Therapeutics stock price target on FDA trial recommendation - Investing.com Canada
Guggenheim cuts Compass Therapeutics stock price target on FDA trial requirement - Investing.com Canada
HC Wainwright & Co. maintains Buy rating on Compass Therapeutics, $12 price target - TradingView
Citizens cuts Compass Therapeutics stock price target on FDA trial request - Investing.com Canada
COMPASS THERAPEUTICS INC. : WEDBUSH CUTS TO NEUTRAL FROM OUTPERFORM; CUTS TARGET PRICE TO $1 FROM $5 - Bitget
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside - Stocktwits
Wedbush downgrades Compass Therapeutics stock rating on FDA trial concerns - Investing.com Canada
Why Did Compass Therapeutics Stock Plunge Today?Compass Therapeutics (NASDAQ:CMPX) - Benzinga
Compass shares fall after FDA tovecimig feedback - grafa.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback - Investing News Network
Compass Therapeutics stock price target maintained at $6 by Stifel - Investing.com Canada
Compass Therapeutics Faces FDA Pushback on Tovecimig Trial - TipRanks
Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares Fall - marketscreener.com
Form 8K Compass Therapeutics, Inc. For: 22 September By Investing.com - Investing.com Nigeria
CMPX Stock Slides As Traders Watch Volatile Support Zone - StocksToTrade
Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback - TradingView
Compass Therapeutics drops as FDA seeks additional trial for lead asset - TradingView
Compass Therapeutics says FDA recommends survival trial before BLA for tovecimig in biliary tract cancer - TradingView
Compass Therapeutics, Inc. Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback - marketscreener.com
Compass Therapeutics’ CMPX Is Still Waiting On Its BLA Moment - Finimize
CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compass (CMPX) Earnings Update: The EPS Result Is Below Expectation in the Current Update; After Earnings: Shares Finish 0.21% Higher on the DayProfit Cycle Analysis - vinanet.vn
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass (CMPX) Session: Finishes 4.23% Lower at $2.38; Technical Setup: the Supplied Trading Band Runs From $2.26 to $2.50 in the Current UpdateDollar Neutral Pair - vinanet.vn
NEXTBio Capital Management LP's Compass Therapeutics Inc(CMPX) Holding History - GuruFocus
Compass (CMPX) Earnings Data Review: The EPS Result Is Below Expectation in the Available Record; Investor Response: Shares Close 3.46% Higher in the Latest SessionCore Business Growth - vinanet.vn
Compass Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate - Moomoo
Compass Therapeutics (CMPX) Climbs 3.26% to $2.22, Approaches Key ResistanceCovered Call Trade - vinanet.vn
HC Wainwright Issues Pessimistic Estimate for CMPX Earnings - MarketBeat
Compass Therapeutics Inc. (CMPX) Stock News Today - TradingKey
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $6 to $7 - Moomoo
Compass Therapeutics Inc (CMPX) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.87%
大文字化:
|
ボリューム (24 時間):